Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Vabysmo (Faricimab)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Vabysmo (faricimab-svoa) is a bispecific monoclonal antibody designed for intravitreal use in the treatment of retinal vascular diseases. It uniquely targets and inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), two key mediators involved in vascular leakage, neovascularization, and inflammation in the retina. Vabysmo is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). By dual inhibition of Ang-2 and VEGF-A, Vabysmo helps stabilize blood vessels and reduce disease activity, offering extended dosing intervals for many patients.

    Fact Table

    Formula

    C6464H9954N1714O2026S46

    License

    US FDA (2022), EMA (2022)

    Bioavailability

    Administered intravitreally; local effect in retina

    Legal status

    Rx-only

    Chemical Name

    Faricimab-svoa

    Elimination half-life

    ~7.5 days (vitreous); systemic ~8 days

    Dosage (Strength)

    120 mg/mL in 0.05 mL solution (6 mg dose)

    Pregnancy

    Use only if clearly needed; limited human data

    Brands

    Vabysmo

    Protein binding

    Not applicable (monoclonal antibody)

    PubChem CID

    249646852

    MedlinePlus

    a622047

    ChEBI

    Not assigned

    ATC code

    S01LA08

    DrugBank

    DB16335

    KEGG

    D12491

    Routes of administration

    Intravitreally (injection into the eye)

    Directions

    Vabysmo is administered by intravitreal injection by a qualified ophthalmologist under sterile conditions.

    nAMD: 6 mg intravitreally every 4 weeks for the first 4 doses, followed by maintenance dosing every 8, 12, or 16 weeks based on disease activity.

    DME: 6 mg intravitreally every 4 weeks for the first 4 doses, then individualized maintenance dosing every 8 to 16 weeks.

    The dosing schedule is determined by retinal imaging and clinical assessment. Both eyes may be treated if necessary, but not on the same day.

    Ingredients

    Active Ingredient: Faricimab-svoa

    Inactive Ingredients: L-histidine, polysorbate 20, sucrose, and water for injection. The formulation is preservative-free and supplied as a sterile solution in a single-dose vial for intravitreal injection.

    Contraindications

    Vabysmo is contraindicated in patients with:

    Ocular or periocular infections

    Active intraocular inflammation

    Known hypersensitivity to faricimab or any component of the formulation

    Cautions

    Intravitreal injections, including Vabysmo, are associated with risks such as endophthalmitis, retinal detachment, and increased intraocular pressure. Patients should be monitored post-injection and instructed to report symptoms such as eye pain, visual changes, or increased redness. Use with caution in patients with a history of stroke or thromboembolic events, as VEGF inhibition may theoretically increase vascular risk. Bilateral treatment on the same day is not recommended due to the risk of bilateral complications.

    Side Effects

    Common side effects include:

    Conjunctival hemorrhage

    Eye pain

    Vitreous floaters

    Increased intraocular pressure

    Less common but serious adverse events:

    Endophthalmitis

    Retinal vasculitis

    Retinal artery occlusion

    Retinal detachment

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 15195

  • Product Reviews